Core Insights - Multiple equity funds have increased their stock positions in Q2 2025, with a focus on sectors such as robotics, fintech, and pharmaceuticals [1][4][5] Fund Performance and Strategy - As of the end of Q2, several funds reported stock positions exceeding 80%, with notable increases in positions for funds like Tongtai Yuanjian Mixed, which rose from 78.65% to 85.74%, and Tongtai Industrial Upgrade Mixed, which jumped from 1.62% to 90.16% [2][3] - Longcheng Fund's pharmaceutical-themed funds achieved significant net value growth, with Longcheng Pharmaceutical Industry Selected Mixed A and C shares recording growth rates of 35.86% and 35.72% respectively [3] Sector Focus - The investment focus varies among funds, with some shifting their portfolios. For instance, Tongtai Industrial Upgrade Mixed transitioned from banking stocks to robotics, while Tongtai Financial Selected Stock maintained a focus on long-term investments in the financial sector [3] - The investment strategy of Debang New Return Flexible Configuration Mixed involves a mix of fixed income and equity assets, with a focus on banks, white goods, public environmental protection, and gold [3] Future Investment Opportunities - Fund managers are optimistic about investment opportunities in robotics, pharmaceuticals, and fintech. The robotics sector is expected to see significant growth driven by increased orders from leading manufacturers and advancements in large model technology [4] - In the pharmaceutical sector, there is anticipation for the growth of innovative drugs, particularly in overseas licensing and domestic sales, with expectations tied to quarterly reports and negotiations with medical insurance [5][6] - The financial sector is viewed as having potential for performance elasticity, especially if the A-share market rebounds, which could benefit brokerage, asset management, and proprietary trading businesses [6]

明日主题前瞻 1、RISC-V | 据央广网，第五届RISC-V中国峰会将于2025年7月16至19日在上海张江科学会堂隆重举办，本届峰会设置1场主论坛、9场垂直领域分论坛、5场 研习会、11项同期活动，以及4,500平方米未来科技展览区。预计将吸引近2.000名国内外专业观众线下参与(80%来自产业界)，线上直播及回放覆盖超过50万 人次行业人群，汇聚数百家企业、研究机构及开源技术社区参会。 点评：天风证券表示，RISC-V架构作为全球三大指令集架构之一，以其开源免费、设计灵活、低功耗等优势，正在迅速崛起。据预测，到2030年，RISC-V 架构产品出货量的年复合增长率将达到40%以上。华泰证券表示，中国RISC-V发展体现在软件、应用及开发者生态三个方面，RISC-V架构由于具备开源开 放的特殊属性，被认为是国产芯片弯道超车的机遇。 2、创新药 | 据智通财经，国家医保局公布《2025年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》，明确 2025年基本医保药品目录调整和商业健康保险创新药品目录制定将同步进行。另外，2000亿市值CXO龙头药明康德披露业绩预告，公司预 ...

Investment Rating - The report indicates a positive investment outlook for the hereditary angioedema (HAE) treatment sector, particularly following the approval of the first oral on-demand treatment, sebetralstat [14][21]. Core Insights - The report highlights the urgent need for effective HAE treatments due to the high risk of life-threatening episodes, with nearly half of HAE patients facing potential asphyxiation [10][16]. - Sebetralstat, approved by the FDA, is noted for its rapid onset of action, achieving near-complete inhibition of plasma kallikrein within 15 minutes of administration [21]. - The KONFIDENT trial results demonstrate that sebetralstat significantly reduces symptom relief time compared to placebo, with median relief times of 1.61 hours for the 300 mg dose and 1.79 hours for the 600 mg dose [20][21]. Summary by Sections Section 1: HAE Overview - HAE is characterized by recurrent episodes of angioedema without urticaria, with a prevalence of approximately 1.5 per 100,000 individuals [7]. - The disease can lead to severe complications, including laryngeal edema, which has a mortality rate of up to 40% among patients [7][10]. Section 2: Current Treatment Landscape - Existing treatments include long-term preventive therapies (LTP) and on-demand treatments for acute episodes [10][11]. - The global HAE drug market reached $2.9 billion in 2022, with $2 billion attributed to long-term prevention and $900 million to acute on-demand treatments [13]. Section 3: Sebetralstat Approval and Efficacy - Sebetralstat is the first oral on-demand treatment for HAE, approved on July 7, 2025, and is expected to address unmet needs in the treatment landscape [21]. - The KONFIDENT trial, involving 136 patients across 20 countries, confirmed the efficacy and safety of sebetralstat, showing significant improvements in symptom relief and severity reduction compared to placebo [21]. Section 4: Future Developments - Pharvaris is developing deucrictibant, a competitive oral antagonist for HAE, with promising Phase II trial results indicating effective management of HAE attacks [26]. - The report anticipates further advancements in HAE treatments, with ongoing clinical trials expected to yield additional data in the coming years [26].

Investment Rating - The report maintains an investment rating of "Leading the Market - A" [9] Core Insights - The report highlights that several newly included innovative drugs in the medical insurance directory are rapidly entering hospitals, with significant growth in the number of drugs entering hospitals by the end of May 2025 compared to April 2025 [2][22] - The report notes that the new drug sector has shown a strong performance, with notable increases in stock prices for companies such as Beihai Kangcheng (114.5%), Frontier Biotech (41.4%), and Junsheng Tai (29.4%) during the week of July 7 to July 13, 2025 [1][18] Summary by Sections Weekly New Drug Market Review - From July 7 to July 13, 2025, the top five companies in the new drug sector by stock price increase were Beihai Kangcheng (114.5%), Frontier Biotech (41.4%), Junsheng Tai (29.4%), Kaituo Pharmaceutical (20.7%), and Yongtai Biotech (20.1%) [1][18] - The top five companies by stock price decrease were Yiming Anke (-19.4%), Shenzhou Cell (-13.4%), Ascentage Pharma (-10.0%), Lepu Biotech (-8.9%), and Rongchang Biotech (-8.8%) [1][18] Key Analysis of the New Drug Industry - The National Medical Insurance Administration updated the hospital admission data for innovative drugs included in the medical insurance directory as of the end of May 2025, indicating rapid hospital admissions for several newly included domestic innovative drugs [2][22] - Notable drugs with fast admission growth included Kangfang Biotech's Cardunilumab and Ivorisumab, Shanghai Yizhong's Paclitaxel Micelle, and Zecjin Pharmaceutical's Recombinant Human Thrombin [2][22] New Drug Approval and Acceptance Status - Four new drug or new indication applications were approved this week, including Ascentage Pharma's Lisatoclax tablets and Zhejiang Tianyuan's quadrivalent influenza virus split vaccine [26][27] - Ten new drug applications were accepted, including Dali Yingjie’s Docetaxel Injection and Zhaoke Pharmaceutical's Atropine Sulfate Eye Drops [26][28] Clinical Application Approval and Acceptance Status - This week, 43 new drug clinical applications were approved, and 20 new drug clinical applications were accepted [4][28]

Investment Rating - The report rates the pharmaceutical industry as "Overweight," indicating a positive outlook for the sector compared to the overall market performance [2][30]. Core Insights - The pharmaceutical sector saw a weekly increase of 1.8%, outperforming the Shanghai Composite Index, which rose by 1.1% [3][4]. - The National Healthcare Security Administration officially launched the 2025 medical insurance catalog adjustment, introducing a commercial health insurance innovative drug catalog for the first time, focusing on high-innovation and clinically valuable drugs [10]. - China has imposed restrictions on the procurement of medical devices from the EU, affecting government purchases exceeding 45 million RMB [10]. - Merck announced a $10 billion acquisition of Verona Pharma, focusing on a new COPD drug, marking a significant transaction in the pharmaceutical sector [11]. Market Performance - The pharmaceutical and biotechnology index increased by 1.8%, ranking 16th among 31 sub-industries [3][4]. - The overall valuation of the pharmaceutical sector stands at 30.2 times PE for 2025E, ranking 6th among 31 primary industries [4][9]. Key Events - The adjustment of the medical insurance catalog officially commenced on July 10, 2025, with a submission period for eligible entities from July 11 to 20 [10]. - The Chinese government has taken measures to restrict the procurement of certain medical devices from the EU, impacting the competitive landscape [10]. - Merck's acquisition of Verona Pharma is a notable event, emphasizing the trend of large-scale business development transactions in the innovative drug sector [11]. Investment Analysis - The innovative drug sector has shown rapid growth in product revenue and licensing deals over the past three years, with significant business development transactions occurring this year [11]. - Companies to watch include Heng Rui Medicine, Bei Da Medicine, and WuXi AppTec, which are expected to benefit from the upcoming changes in the medical insurance catalog and the overall growth in the innovative drug market [11].

Group 1 - The index is expected to consolidate and gather strength before reaching new highs, with the recent tariff delay being fully priced in by the market, leading to a rise in major indices, including the Shanghai Composite Index reaching a high of 3555.22 points [3][14] - The market's optimistic sentiment is currently prevailing, but there is insufficient risk pricing for potential negative surprises regarding tariffs, which may hinder further declines in risk evaluation [3][14] - The market's recent rise is primarily driven by an increase in risk appetite, with the ChiNext Index, CSI 1000 Index, and All A Index outperforming the Shanghai Composite Index [4][15] Group 2 - Short-term themes are expected to rotate between policy expectations and industrial trends, with a focus on the "anti-involution" sector and real estate, which has seen a 6.1% increase this week due to anticipated policy developments [6][16] - The "anti-involution" sector, particularly in steel, pork, and certain segments of new energy, is highlighted as a potential area of focus due to high policy expectations following recent government meetings [6][16] - The trading of industrial trends is expected to continue, with short-term attention on sectors such as stablecoins, rare earths, nuclear fusion, military industry, deep-sea economy, artificial intelligence, and innovative pharmaceuticals [7][17]

2025年7月11日，中共中央政治局委员、外交部长王毅在吉隆坡会见美国国务卿鲁比奥。双方就中美关系以及共同关心的问题交换了意见。王毅全面阐述了中方对 发展中美关系的原则立场，强调双方应将两国元首重要共识转化为具体政策和行动。希望美方以客观、理性、务实态度看待中国，以和平共处、合作共赢为目标制 定对华政策，以平等、尊重、互惠方式同中方打交道，共同找到一条新时期中美正确相处之道。 双方一致认为会晤是积极、务实、建设性的，同意加强外交渠道及各领域各层级沟通对话，发挥外交部门在推动两国关系中的作用，在管控分歧的同时，探索扩大 合作领域。 02 重磅改革落地，科创成长层来了 科创板"1+6"政策配套业务规则来了！7月13日，上交所正式发布实施进一步深化科创板改革配套业务规则，包括《科创板上市公司自律监管指引第5号——科创成 长层》《发行上市审核规则适用指引第7号——预先审阅》《发行上市审核规则适用指引第8号——资深专业机构投资者》3项业务指引，以及修订的《会员管理业 务指南第2号——风险揭示书必备条款》和《证券交易业务指南第6号——证券特殊标识》2项业务指南。 根据配套业务规则，科创板存量32家未盈利企业将自《科创成长 ...

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, particularly for 2025, suggesting a potential for diverse investment opportunities as the sector recovers from low valuations and public fund allocations [10]. Core Insights - The pharmaceutical sector is currently experiencing low valuations, with public funds under-allocating to this area. The report anticipates a recovery driven by macroeconomic factors and significant product launches [10]. - The report emphasizes a shift in the innovative drug sector from quantity to quality, highlighting the importance of differentiated products and international expansion for profitability [10]. - The medical device sector is seeing a rebound in bidding volumes, particularly in imaging equipment, and is expected to benefit from domestic product upgrades and international market expansion [10]. - The report identifies a growing trend in the CXO and life sciences services sector, with expectations for increased investment and a recovery in demand [10]. - The traditional Chinese medicine sector is projected to benefit from policy changes and market dynamics, with specific companies recommended for investment based on their unique product offerings and market positions [12]. Summary by Sections Market Review - The report notes a 1.80% increase in the CITIC Pharmaceutical Index, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 sectors [7]. - The top-performing stocks include Frontline Bio-U, MediWest, and Lianhuan Pharmaceutical, while the worst performers include ST Weiming and Innovent Biologics [7]. Overall Perspective and Investment Themes - The report suggests that the pharmaceutical industry is poised for growth, with a focus on innovative drugs, medical devices, and traditional Chinese medicine. Specific companies are highlighted for their potential in these areas [10][12]. - The report also discusses the implications of policy changes and market trends for the pharmaceutical and medical device sectors, indicating a favorable environment for investment [10][12]. Company-Specific Insights - Companies like Baiyi, Xinda, and Kangfang are highlighted for their innovative drug pipelines and potential for growth in the coming years [10][12]. - The report provides detailed insights into the clinical progress of various drugs across different companies, indicating a robust pipeline that could drive future revenue [13][20][24][30][35][38].

Group 1 - The Shanghai Composite Index successfully surpassed 3500 points, reaching a new high for the year, with a weekly increase of 1.09% [1] - The financial sector, particularly the banking and brokerage stocks, played a significant role in driving the index higher, with major banks hitting historical price records [1] - The trading volume increased notably, with a peak of 1.71 trillion yuan on July 11, marking the highest level since March 15 [1] Group 2 - Several companies released their mid-year performance forecasts for 2025, leading to a rise in related sectors, particularly in rare earths, where North Rare Earth reported significant year-on-year increases in revenue and net profit [3] - The pharmaceutical sector also saw a collective rise in AH shares, while sectors like photovoltaic, steel, coal, and construction experienced upward momentum due to favorable news [3] - The upcoming implementation of the stablecoin regulations in Hong Kong has kept the blockchain and digital currency concepts active, with Shanghai's government exploring blockchain applications in cross-border trade and supply chain finance [3] Group 3 - The consumer sector showed volatility, with an initial boost from increased restaurant sales due to price wars among delivery platforms, but later saw declines in new consumption stocks [4] - The "new consumption trio" stocks, including Lao Pu Gold, Pop Mart, and Mixue Ice City, experienced significant drops, raising concerns about the sustainability of the new consumption trend [4]

Core Viewpoint - The report highlights the performance and investment strategy of the Great Wall Healthcare Mixed Securities Investment Fund for the second quarter of 2025, emphasizing its focus on the healthcare industry and the fund's net value growth during the period [1][10]. Fund Overview - Fund Name: Great Wall Healthcare Mixed Fund - Fund Code: 000339 - Fund Type: Contractual open-end fund - Total Fund Shares at Period End: 117,458,484.44 shares - Investment Objective: Focus on listed companies in the healthcare industry, aiming for performance that exceeds the benchmark while controlling risks [1][2]. Investment Strategy - The fund employs a mixed investment strategy, adjusting asset allocation based on market conditions. It combines top-down and bottom-up approaches to analyze macroeconomic factors and the fundamentals of investable stocks [2][3]. - The healthcare sector includes various sub-industries such as pharmaceuticals, traditional Chinese medicine, biological products, medical services, and medical devices. The fund selects outstanding companies from these sub-industries for its stock portfolio [2][3]. Performance Benchmark - The performance benchmark is composed of 90% of the CSI Pharmaceutical and Health Index return and 10% of the China Bond Composite Wealth Index return [3]. Risk and Return Characteristics - The fund is characterized by a long-term average risk and expected return that is lower than equity funds but higher than bond and money market funds, categorizing it as a high-risk, high-return product [3]. Financial Performance - The net value growth rate of the Great Wall Healthcare Mixed Fund A for the past three months was 17.49%, while the benchmark return was 1.41% [10]. - Over the past six months, the fund's growth rate was 2.23%, compared to a benchmark return of 32.19% [10]. - The fund's performance over the past year showed a net value growth rate of 35.19%, with a benchmark return of 10.13% [10]. Investment Composition - As of the report period, the fund's total assets included approximately 265,126,026.09 yuan in stocks, accounting for 71.42% of the total fund assets [11]. - The fund's investment strategy mandates that at least 80% of its non-cash assets be invested in stocks of listed companies in the healthcare sector [6]. Fund Management - The fund manager, Great Wall Fund Management Co., Ltd., has adhered to relevant laws and regulations, ensuring the fair treatment of different investors and maintaining a disciplined investment approach [7][9].